|Bid||24.48 x 1000|
|Ask||24.52 x 800|
|Day's range||24.40 - 25.73|
|52-week range||13.84 - 51.59|
|Beta (5Y monthly)||-0.08|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Dec 2012|
|1y target est||N/A|
While Cassava Sciences, Inc. (NASDAQ:SAVA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 22%...
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though its clinical trials have (so far) shed little light on the issue. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam, the market reacted quite negatively to the release of new data that management spun as being positive.
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.